Kiniksa Pharmaceuticals Intern - COM (KNSA)

CUSIP: G5269C101

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / COM
Total 13F shares
31,540,540
Share change
+1,534,152
Total reported value
$339,374,716
Put/Call ratio
58%
Price per share
$10.76
Number of holders
129
Value change
+$13,098,378
Number of buys
76
Number of sells
48

Quarterly Holders Quick Answers

What is CUSIP G5269C101?
CUSIP G5269C101 identifies KNSA - Kiniksa Pharmaceuticals Intern - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2023

As of 31 Mar 2023, Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by 129 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,540,540 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, Rubric Capital Management LP, STATE STREET CORP, PICTET ASSET MANAGEMENT SA, MORGAN STANLEY, HHLR ADVISORS, LTD., ArrowMark Colorado Holdings LLC, and Hudson Bay Capital Management LP. This page lists 129 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.